Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Isabel Huber

CEO and co-founder

SUCCIPRO

Tarragona, Spain

2 profile visits

AI‑engineered enzyme SD1253 lowers gut succinate to reduce inflammation, offering a first‑in‑class, disease‑modifying oral therapy for IBD.

My organisation

Succipro is a spin-off from the Pere i Virgili Health Research Institute (IISPV) and the Rovira i Virgili University, dedicated to creating innovative pharmaceutical solutions for the treatment of inflammatory and metabolic diseases. They work to transform pioneering scientific discoveries into therapies that improve the quality of life for patients. Succipro stands out for its first-in-class therapies (i.e., the first in their category), leading innovation in drug development to address unmet medical needs. Their research focuses on: Succinic Acid as a therapeutic target: A pioneering strategy for the treatment of metabolic diseases. Personalized therapy: The application of biomarkers to design treatments tailored to the specific needs of each patient. Safety and efficiency: A commitment to creating drugs that minimize adverse effects, always prioritizing patient safety.
Read more

About me

Pharmacist with a PhD in Biochemistry (University of Barcelona, Spain),I trained at VHIO and later joined Mosaic Biomedicals, a VHIO spin-off whose cancer therapy was licensed to AstraZeneca. In 2018, I became Head of Innovation at IISPV’s DIAMET group, managing patents and preclinical strategies while completing an MBA. Recognized among the top 10 female entrepreneurs in Catalonia (EAE Business School, 2024) and awarded 4th place (among 149 projects worldwide) at the global Women Entrepreneur Competition (TARA Foundation), I now lead SUCCIPRO, for which I have raised 2,6 M€ in dilutive and non-dilutive funding.

Social media